Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

The recent outbreak of coronavirus disease 2019 (COVID‐19), caused by the Severe Acute
Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) has resulted in a world‐wide …

Nonalcoholic fatty liver disease is the most prevalent liver disease worldwide, affecting 20%–
25% of the adult population. In 25% of patients, nonalcoholic fatty liver disease progresses …

Nonalcoholic steatohepatitis (NASH) is a progressive disorder with aberrant lipid
accumulation and subsequent inflammatory and profibrotic response. Therapeutic efforts at …

Background and Aims HSCs and portal fibroblasts (PFs) are the major sources of collagen‐
producing myofibroblasts during liver fibrosis, depending on different etiologies. However …

Non-alcoholic fatty liver disease (NAFLD), the most prevalent liver pathology worldwide, is
intimately linked with obesity and type 2 diabetes. Liver inflammation is a hallmark of NAFLD …

Production of amphiregulin (Areg) by regulatory T (Treg) cells promotes repair after acute
tissue injury. Here, we examined the function of Treg cells in non-alcoholic steatohepatitis …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide. It is strongly associated with obesity, type 2 diabetes (T2DM), and other …

Fibrosis is characterized by the excessive production of collagen and other extracellular
matrix (ECM) components and represents a leading cause of morbidity and mortality …